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. . .the concept of
safety does not in-
clude the freedom
from adverse effects,
but rather that any
risk is outweighed
by the benefit
produced.The warning of the risk of diabetes and cognitive dysfunction recently added tothe safety information of statin drugs by the Food and Drug Administration(FDA) reinforced my impression that there is now an excessive focus upon the
dverse effects of drugs and devices. This impression has gradually formed over a
umber of years, fostered in part by the media attention accompanying the withdrawal
f drugs, such as rofecoxib, and the delayed approval of therapeutic devices, such as
ranscatheter valves. So I decided to confirm this suspicion by researching the topic. As
s so often the case, I was surprised at the considerable literature on the risk–benefit
atio, and that the issue was much more complex than I had envisioned. Although an
ditor’s Page is inadequate to address the subject adequately, it can certainly serve to
onvey some general thoughts.
In the process of researching the literature, I encountered an enlightening and very
ntertaining article by Louis Lasagna that I highly recommend (1). He points out that
utrageous medications and claims of benefits were quite prevalent in the distant past,
ncluding Mrs. Winslow’s Soothing Syrup to relax children that contained morphine,
nd the advertisement regarding Hamlin’s Wizard Oil that “there was no sore that it
ill not heal, no pain it will not subdue.” The Food and Drug Act of 1906 established
he agency to address dangerous practices in meat processing and the preparation and
se of pharmaceutical agents. In 1962, following the adverse effects of thalidomide, the
ct was amended and the attention of Congress regarding the FDA became focused on
afety. In fact, it was not until the AIDS epidemic that the issue of the availability of
edications came to the forefront. It should not be surprising, therefore, if the FDA
ere more disposed to the sin of omission of not approving an effective modality than to
he sin of commission of approving one with serious adverse effects.
Despite the suspicions of an excessive emphasis upon safety engendered by the forego-
ng, the clearly stated mission of the FDA is to assure the safety, efficacy, and security of
uman drugs, biological products, and medical devices and to help speed innovations
hat make medicines more effective, safer, and more affordable. In this regard, the con-
ept of safety does not include the freedom from adverse effects, but rather that any risk
s outweighed by the benefit produced. However, the means by which this is decided is
ot clear cut, and certainly very complex. There is no established quantitative method
or this determination, and at least 12 approaches exist in the literature (2), including
et number needed to treat or harm, the risk–benefit plane and contour, multicriteria
ecision analysis, and the stated preference method. However, after extensive examina-
ion and analysis of these methods, all that investigators could conclude was that “multi-
le risk–benefit assessment approaches across different therapeutic indications and treat-
ent populations should be undertaken to bound the risk–benefit profile (2).”
An interesting paper by Cohen and Neumann (3) illustrates the variables inherent
n risk–benefit assessment by comparing the danger of taking aspirin to that of driv-
ng a car. Regarding risk, the authors indicated there is typically limited information
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Editor’s Page July 17, 2012:233–4prior to drug approval, and post-marketing data are of-
en insufficiently comprehensive for this determination.
rug therapy may be mandatory or discretional. The
agnitude of any adverse event can vary considerably, as
an the number of side effects. The risk of adverse event
ay be near- or far-term, and the duration and intensity
f administration required for risk may differ considerably.
he characteristics of the individual, including age, co-
orbidities, and so on, may greatly influence the risk in-
olved in any intervention. The perception and acceptabil-
ty of risk may differ substantially among individuals,
ncluding the perceived catastrophic nature and “dread” of
he event, its newness or familiarity, and the degree of
ublic attention that it attracts. Inherent in this last issue
s the supremely important factor of the freedom to ac-
ept any given risk, and the differences that individuals
xhibit in this characteristic. Taking these variables into
onsideration as much as possible, the Cohen and Neu-
ann (3) paper concluded that the mortality risk of aspi-
in (via stroke) was equivalent to that of driving a car.
Not considered in the above analysis, of course, was the
enefit of any action or intervention. Just as the risk in-
rinsic to any medical treatment has multiple variables, so
oes the benefit. Obviously, the more severe the outcome
f the condition being treated, the greater the risk that is
arranted for the benefit of its remedy. The benefit
ought may be partial or complete, and may have a high
r low degree of certainty of occurring. As is true of risk,
omprehensive data regarding the likelihood of benefit
hroughout a wide population is often lacking. Again,
ndividuals may differ widely in the degree of distress that
hey experience with any signs or symptoms of a disorder,
nd the degree of risk they are willing to take to elimi-
ate or reduce them.
It is apparent that the FDA, or any other international
gency charged with the task, faces a formidable challenge
n assuring the safety and efficacy of medical interven-
ions. It is not surprising, therefore, that no uniform
uantitative methodology is regularly employed in making
hese assessments. This does raise the specter, however,
hat subconscious bias could lead to greater emphasis
pon risk than benefit, and to a somewhat cautious ap-
roach to drug and device approval. The regulatory pro-
ess of the FDA in the United States seems to be more
igorous than elsewhere in the world, a policy for which
alid arguments can be advanced. While the value of thisrigor may be debated, it does have the potential to delay
the availability of effective therapies to patients. The
greatest impact occurs when the FDA makes a decision
for society as a whole that a drug or device is not to be
approved and, therefore, is not available. Those decisions
hopefully provide protection from dangerous interventions
for individuals who are incapable of or unwilling to make
risk–benefit assessments. However, they deny the option
of choice to those who desire to and can make such eval-
uations, and also can have the potential to dampen the
willingness of innovators to try to bring their discoveries
to the marketplace.
As stated in the opening paragraph, determination of
the risk–benefit ratio of any medical intervention is com-
plex at best, always challenging, and continues to be a
frequently discussed in the literature. I believe that the
professionals of the FDA who are charged with making
these decisions are hard working and dedicated. Thank
goodness that I do not have to make the judgments that
are required of them. Not uncommonly they must reach
verdicts in the absence of absolute certainty, and in the
setting of external pressures. Society can help them in this
regard by recognizing that safe does not mean without
adverse events, but rather that the benefits outweigh the
risks. While the occurence of significant adverse effects
will almost certainly attract more attention than the ab-
sence of an effective therapy, the impact upon society of
the latter may be much greater. We have to be willing to
accept that a few may be injured so that many may be
benefited.
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